{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:00:46Z","timestamp":1790830846713,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Conversion therapy may create an opportunity for liver resection in selected patients with initially unresectable hepatocellular carcinoma (HCC), but reported conversion rates use heterogeneous denominators and endpoints. We estimated actual completed hepatectomy using a verified all-treated denominator.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed\/MEDLINE, Embase, Web of Science Core Collection, Cochrane Library\/CENTRAL, Wanfang Data, and CNKI were searched through April 10, 2026. Eligible cohorts included initially or baseline unresectable HCC, an all-treated denominator, and completed liver resection events. Two authors independently assessed eligibility, extracted data, and evaluated risk of bias. Random-effects logit proportion meta-analysis, Hartung-Knapp sensitivity, prediction intervals, leave-one-out analyses, treatment-strategy subgroups, publication-year meta-regression, and small-study-effect diagnostics were undertaken. PROSPERO: CRD420261360108.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-seven reports represented 36 unique studies; 34 studies involving 5,137 patients and 1,042 completed hepatectomies entered the quantitative synthesis. The crude aggregate resection rate was 20.3% (1,042\/5,137), whereas the random-effects modeled pooled rate was 25.40% (95% CI, 20.74%-30.69%; I\n                      <jats:sup>2<\/jats:sup>\n                      =91.5%; tau\n                      <jats:sup>2<\/jats:sup>\n                      =0.5132). The Hartung-Knapp 95% CI was 20.12%-31.51%, and the prediction interval was 7.16%-60.04%. Leave-one-out estimates ranged from 24.52% to 26.64%. Treatment-strategy differences were not statistically significant (Qm=5.17, df=2, P = 0.075). Publication-year meta-regression did not show a clear linear association (OR per decade 1.19, 95% CI 0.77-1.83; P = 0.440), and Egger\u2019s test did not indicate significant funnel asymmetry (P = 0.381).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately one-quarter of patients initiating conversion therapy underwent actual hepatectomy, but the crude and modeled estimates differ because substantial heterogeneity changes random-effects study weighting. The pooled estimate is a cross-study, cross-era benchmark for multidisciplinary decision-making rather than a universal patient-level probability or a treatment-specific efficacy estimate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420261360108.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1898480","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:49:45Z","timestamp":1790830185000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Resection rates after conversion therapy for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaobo","family":"Ouyang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, People\u2019s Hospital of Chongqing Hechuan","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, People\u2019s Hospital of Chongqing Hechuan","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of General Practice, People\u2019s Hospital of Chongqing Hechuan","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, People\u2019s Hospital of Chongqing Hechuan","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, The Affiliated Banan Hospital of Chongqing Medical University (People\u2019s Hospital of Banan District)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoren","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Shapingba Hospital Affiliated to Chongqing University (Shapingba District People\u2019s Hospital of Chongqing)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Che","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Shapingba Hospital Affiliated to Chongqing University (Shapingba District People\u2019s Hospital of Chongqing)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.978823","article-title":"Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: a systematic review and meta-analysis","volume":"12","author":"Pei","year":"2022","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3892\/ol.2024.14398","article-title":"Lenvatinib-based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"27","author":"Li","year":"2024","journal-title":"Oncol Lett"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s12885-024-12772-y","article-title":"Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12885-025-15449-2","article-title":"The effectiveness and safety of immune checkpoint inhibitors in conversion or neoadjuvant therapy for hepatocellular carcinoma: a meta-analysis and systematic review","volume":"26","author":"Hu","year":"2026","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0094","article-title":"Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization? Ten years of experience","volume":"21","author":"Zhang","year":"2016","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03767-4","article-title":"Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study","volume":"148","author":"Chen","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/AS9.0000000000000057","article-title":"Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma","volume":"2","author":"Li","year":"2021","journal-title":"Ann Surg Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-5671.2021.04.15","article-title":"Efficacy of TACE combined with TKI and PD-1 inhibitors in conversion therapy for patients with unresectable hepatocellular carcinoma","volume":"13","author":"Wei","year":"2021","journal-title":"Chin J Oncol Prev Treat"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.729764","article-title":"Surgical conversion for initially unresectable locally advanced hepatocellular carcinoma using a triple combination of angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy: a retrospective study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000514313","article-title":"Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations","volume":"10","author":"Zhu","year":"2021","journal-title":"Liver Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.923566","article-title":"Conversion therapy of large unresectable hepatocellular carcinoma with ipsilateral portal vein tumor thrombus using portal vein embolization plus transcatheter arterial chemoembolization","volume":"12","author":"He","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrac114","article-title":"Conversion therapy for initially unresectable hepatocellular carcinoma using toripalimab, lenvatinib plus TACE: a real-world study","volume":"6","author":"Qu","year":"2022","journal-title":"BJS Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B18","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2022"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B20","unstructured":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations\n          \n          \n          2013"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1110689","article-title":"Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.11.027","article-title":"Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: a real-world observational study","volume":"56","author":"Li","year":"2024","journal-title":"Dig Liver Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn113884-20240719-00219","article-title":"Analysis of the efficacy and safety of FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma","volume":"30","author":"Lu","year":"2024","journal-title":"Chin J Hepatobiliary Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0159","article-title":"Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor for treating unresectable hepatocellular carcinoma","volume":"85","author":"Bai","year":"2024","journal-title":"Br J Hosp Med (Lond)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-025-02498-z","article-title":"Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study","volume":"11","author":"Zhang","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S404500","article-title":"Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitor and immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a single-center experience","volume":"10","author":"Pan","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2026.112724","article-title":"Development and validation of a nomogram to predict surgical resection after conversion therapy in unresectable hepatocellular carcinoma","volume":"197","author":"Su","year":"2026","journal-title":"Eur J Radiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000547725","article-title":"Conversion therapy based on TACE\/HAIC-based treatment to improve the therapeutic effect of initially unresectable hepatocellular carcinoma","volume":"15","author":"Lin","year":"2026","journal-title":"Liver Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102367","article-title":"Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study","volume":"67","author":"Wu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1115109","article-title":"Sintilimab plus lenvatinib conversion therapy for intermediate\/locally advanced hepatocellular carcinoma: a phase 2 study","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000475","article-title":"Selective internal radiation therapy for unresectable hepatocellular carcinoma: the SIRT downstaging study","volume":"8","author":"Regnault","year":"2024","journal-title":"Hepatol Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn113884-20230310-00074","article-title":"Short-term efficacy and safety analysis of TACE combined with TKI and PD-1 inhibitors in the treatment of initially unresectable hepatocellular carcinoma","volume":"29","author":"Zhang","year":"2023","journal-title":"Chin J Hepatobiliary Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001229","article-title":"Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: survival benefit in intermediate or advanced, but not early, stages","volume":"82","author":"Yang","year":"2025","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3870\/j.issn.1004-0781.2023.11.024","article-title":"Effect analysis of hepatic artery infusion chemotherapy in patients with unresectable hepatocellular carcinoma","volume":"42","author":"Du","year":"2023","journal-title":"Herald Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188308","article-title":"Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.11864\/j.issn.1673.2026.01.06","article-title":"Observation on downstaging conversion effect of sintilimab combined with anlotinib hydrochloride capsules and transarterial chemoembolization in unresectable advanced hepatocellular carcinoma","volume":"21","author":"He","year":"2026","journal-title":"Minim Invasive Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000543994","article-title":"Conversion surgery after immune checkpoint inhibitor-based combination therapy for initially unresectable hepatocellular carcinoma: a retrospective cohort study","volume":"14","author":"Piao","year":"2025","journal-title":"Liver Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3877\/cma.j.issn.2095-3232.2023.01.011","article-title":"Efficacy of lenvatinib and PD-1 inhibitor combined with transcatheter arterial chemoembolization in treatment of unresectable hepatocellular carcinoma","volume":"12","author":"Yang","year":"2023","journal-title":"Chin J Hepat Surg (Electronic Edition)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3877\/cma.j.issn.2095-3232.2025041","article-title":"Hepatic arterial infusion chemotherapy combined with lenvatinib plus PD-1 inhibitor versus HAIC combined with lenvatinib for unresectable hepatocellular carcinoma","volume":"14","author":"Zeng","year":"2025","journal-title":"Chin J Hepat Surg (Electronic Edition)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1186\/s12885-025-14250-5","article-title":"Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial","volume":"25","author":"Yalikun","year":"2025","journal-title":"BMC Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173024","article-title":"Conversion therapy to transplant or surgical resection in patients with unresectable hepatocellular carcinoma treated with boosted dose of yttrium-90 radiation segmentectomy","volume":"16","author":"Son","year":"2024","journal-title":"Cancers"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050166","article-title":"Improved long-term survival for unresectable hepatocellular carcinoma with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I\/II clinical trials","volume":"124","author":"Zeng","year":"1998","journal-title":"J Cancer Res Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v8.i1.74","article-title":"High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma","volume":"8","author":"Chen","year":"2002","journal-title":"World J Gastroenterol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2023_230806N413","article-title":"Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial","volume":"70","author":"Liu","year":"2023","journal-title":"Neoplasma"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S404675","article-title":"Conversion therapy with lenvatinib, sintilimab, and arterially directed therapy in patients with initially unresectable hepatocellular carcinoma","volume":"10","author":"Gan","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"B47","article-title":"Donafenib combined with TACE and camrelizumab as conversion therapy for initially unresectable HCC: a prospective, single-arm, single-center phase II clinical trial","volume":"28","author":"Cao","year":"2023","journal-title":"Clin Oncol J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016736","article-title":"Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2025.01170","article-title":"Radiotherapy enhances triple therapy for conversion and survival in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombus","volume":"19","author":"Zhou","year":"2025","journal-title":"Biosci Trends"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1046584","article-title":"Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: a retrospective study","volume":"12","author":"Yi","year":"2022","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn113884-20240531-00166","article-title":"Transcatheter arterial chemoembolization combined with tislelizumab and tyrosine kinase inhibitor as conversion therapy in initially unresectable hepatocellular carcinoma","volume":"30","author":"Liu","year":"2024","journal-title":"Chin J Hepatobiliary Surg"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573098","article-title":"Lenvatinib versus bevacizumab when combined with PD-1\/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn113855-20250305-00118","article-title":"Comparative study of the efficacy of hepatic artery infusion chemotherapy and transarterial chemoembolization combined with targeted therapy and immunotherapy for unresectable hepatocellular carcinoma","volume":"40","author":"Li","year":"2025","journal-title":"Chin J Gen Surg"},{"key":"B54","article-title":"Efficacy and safety of lenvatinib plus PD-1 inhibitor pretreatment followed by sequential TACE in conversion therapy for initially unresectable liver cancer","volume":"39","author":"Shang","year":"2025","journal-title":"J Chin Pract Diagn Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1159\/000541249","article-title":"Consensus of chinese experts on neoadjuvant and conversion therapies for hepatocellular carcinoma: 2023 update","volume":"14","author":"Bi","year":"2025","journal-title":"Liver Cancer"},{"key":"B57","article-title":"Study-level dataset and reproducible analysis code for \u201cResection Rates after Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-analysis","volume-title":"Zenodo","author":"Ouyang","year":"2026"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1898480\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:50:11Z","timestamp":1790830211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1898480\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":57,"alternative-id":["10.3389\/fonc.2026.1898480"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1898480","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1898480"}}